Be the first person to write a business review for Nuvo Research Inc.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida. PetMed Express, Inc. (PetMed) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company markets its products through national television, online, and direct mail/print advertising campaigns. PetMed offers a selection of products for dogs, cats, and horses. As of March 31, 2009, its product line contains approximately 750 stock keeping units (skus). These products include brands of medication, such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx and Rimadyl.

Pro-Pharmaceuticals, Inc. is a development-stage company engaged in the discovery and development of carbohydrate-based therapeutics. The Company’s therapeutics is used in treatment of liver, microbial and inflammatory diseases. All of its products were in development, including pre-clinical and clinical trials during the year ended December 31, 2008. The Company focuses on the development of a new generation of anti-cancer treatments using carbohydrate polymers to increase survival and improve the quality of life for cancer patients. Its principal pipeline candidate, DAVANAT, is a chemical entity that is in Phase II trials for first-line treatment of colorectal and biliary cancer. In September 2008, the Company submitted a clinical and pre-clinical package to the United States Food and Drug Administration (FDA) in support of its DAVANAT New Drug Application (NDA).

pSivida Corp. company was founded in 1987 and is based in Watertown, Massachusetts. pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The company's products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.